The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...

Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...

Aranesp, biotech giant Amgen Inc.’s once-highflying anemia drug, took another hit Wednesday when the Food and Drug Administration ordered new restrictions on the way physicians prescribe it to cancer ...

STOCKHOLM—Whether darbepoetin alfa (DA) is administered in the middle or at the end of a hemodialysis session has no significant effect on hemoglobin levels, according to a French study. Some in vitro ...

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...

Amgen Inc. is considering revising the safety information on its best-selling drug Aranesp after a new study showed the anemia treatment may increase the likelihood of death in women with cancer.

Shares of Amgen are rallying $1.54, or 4.3 percent, to $37 in pre-open trading after the U.S. Food and Drug Administration approved the biotech firm's Aranesp for the treatment of chemotherapy-induced ...

LOS ANGELES (Reuters) - Amgen Inc dodged a bullet on Thursday when a U.S. advisory panel recommended tighter use of anemia drugs, but said the medicines should remain on the market for most cancer ...

BOSTON, March 13 (Reuters) - Amgen Inc. said on Tuesday it is in discussions with European regulators to update the label on its top-selling anemia drug Aranesp to reflect safety concerns. The world's ...

SAN FRANCISCO (MarketWatch) -- Amgen Inc. late Monday reported a 14% rise in third-quarter profit that was powered by a surge in sales of the biotechnology company's lead product, the anemia treatment ...